Jiangsu Hengrui Medicine
600276.SS
#460
Rank
โ‚น3.754 T
Marketcap
โ‚น588.65
Share price
-1.68%
Change (1 day)
17.13%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Revenue for Jiangsu Hengrui Medicine (600276.SS)

Revenue in 2024 (TTM): โ‚น326.80 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current revenue (TTM ) is โ‚น331.46 Billion. an increase over the revenue in the year 2023 that were of โ‚น268.01 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual revenue

Year Revenue Change
2024 โ‚น333.28 B24.35%
2023 โ‚น268.01 B2.9%
2022 โ‚น260.45 B-12.56%
2021 โ‚น297.88 B0.32%
2020 โ‚น296.93 B24.06%
2019 โ‚น239.35 B31.24%
2018 โ‚น182.38 B38.23%
2017 โ‚น131.94 B16.79%
2016 โ‚น112.97 B15.17%
2015 โ‚น98.09 B28.44%
2014 โ‚น76.37 B22.03%
2013 โ‚น62.58 B32.29%
2012 โ‚น47.30 B26.08%
2011 โ‚น37.52 B50.27%
2010 โ‚น24.97 B21.23%
2009 โ‚น20.59 B23.1%
2008 โ‚น16.73 B63.27%
2007 โ‚น10.24 B28.24%
2006 โ‚น7.99 B22.98%
2005 โ‚น6.49 B12.86%
2004 โ‚น5.75 B-0.44%
2003 โ‚น5.78 B31.99%
2002 โ‚น4.38 B